GSK plc American Depositary Shares (Each representing two Ordinary Shares)
GSKDividend History
Investors can expect a dividend payout of $0.42 per share, scheduled to be distributed in 19 days on January 8, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 8, 2026 | $0.42 | 2025-11-14 | 2025-11-14 |
| October 9, 2025 | $0.43 | 2025-08-15 | 2025-08-15 |
| July 10, 2025 | $0.43 | 2025-05-16 | 2025-05-16 |
| April 10, 2025 | $0.41 | 2025-02-21 | 2025-02-21 |
| January 9, 2025 | $0.38 | 2024-11-15 | 2024-11-15 |
Dividends Summary
- GSK plc American Depositary Shares (Each representing two Ordinary Shares) has issued 92 dividend payments over the past 23 years
- The most recent dividend was paid 72 days ago, on October 9, 2025
- The highest dividend payed out to investors during this period was $0.75 per share
- The average dividend paid during this period was $0.49 per share.
Company News
Merck & Co. has decided not to exercise its option for Evaxion's gonorrhea vaccine candidate EVX-B2 (protein-based version), allowing Evaxion to retain global rights and seek alternative licensing partners. The decision does not impact Evaxion's cash runway extending to mid-2027. Evaxion continues developing an mRNA version with Afrigen Biologics...
Oxford BioTherapeutics has partnered with GSK to discover novel antibody-based cancer therapeutics using their proprietary OGAP®-Verify platform. The multi-year collaboration aims to identify and validate new oncology targets, with GSK driving further research and development.
Leon O. Moulder, CEO of Zenas BioPharma, purchased 36,928 shares through an open-market transaction and announced a licensing deal with InnoCare Pharma for a multiple sclerosis candidate, signaling confidence in the company's potential.
President Trump announced a 100% tariff on branded and patented pharmaceutical products starting October 1, 2025, causing significant market disruption and raising concerns about global pharmaceutical supply chains and trade policy.
Moderna's stock has outperformed the industry, sector, and S&P 500 in 2023, driven by the strong development of its mRNA-based therapeutics. The company plans to launch 15 new products, including an RSV vaccine, over the next five years, reducing its dependence on the COVID-19 vaccine. Moderna's robust pipeline progress and strong cash position m...
